SyneuRx CEO Emil Tsai Named Fellow of National Academy of Inventors Renowned Johns Hopkins and Harvard-educated neuroscience and brain disorder expert is being inducted as a 2022 fellow from prestigious…
SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® Positive results show Pentarlandir is safe and effective in patients with mild-to-moderate COVID-19 Press Release…
Dr. Joseph T. Coyle Named Chair of SyneuRx’s Scientific Advisory Board Renowned neuroscientist known for his groundbreaking discoveries in psychiatric disorders joins advisory board to drive clinical development efforts Press…
SyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01) Early research suggests Pentarlandir is safe to use against COVID-19; Phase 3 trial evaluating…
Q&A with SyneuRx Chief Scientist and CEO, Dr. Emil Tsai: What Are The Top Symptoms of The BA.2 Variant and Is It a Major Cause of Concern? Since the beginning…
SyneuRx Announces Oral COVID-19 Antiviral Drug Candidate Pentarlandir® Is Showing Effectiveness Against Both the Omicron and Delta COVID-19 Variants Acting as Both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir® is…
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir® Has Entered Final Portion of FDA Phase II Testing Based on Highly-Purified Isomers of Tannic Acid and Acting as a Dual…
SyneuRx Announces Closing of Public Offering Press Release Jun 23, 2021 Taipei, Taiwan, June 23, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE:6575) today announced the closing of its public offering…
Taiwan FDA Approves SyneuRx’s IND Application for COVID-19 Clinical Trial Press Release Jun 08, 2021 Taipei, Taiwan, June 8, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE: 6575), announced today that an IND application for…
SyneuRx Files an IND Application for COVID-19 Clinical Trial in Taiwan Press Release Jun 03, 2021 Taipei, Taiwan, June 3rd, 2021 -- SyneuRx International (Taiwan) Corp. (TWSE: 6575), announced today that an IND application for SNB011, using its…
